Phyllis Gotlib, President, International of American Well Corp (AMWL), filed a Form 4 disclosing the sale of 3,573 shares of Class A Common Stock on September 1, 2026, at a price of $11.80 per share. The transaction was a non-discretionary automatic "sell to cover" executed solely to satisfy tax withholding obligations...

Mark Hirschhorn, Chief Financial Officer of American Well Corp, reported the sale of 10,751 shares of Class A Common Stock on September 1, 2026. The shares were sold at a price of $11.8 per share, resulting in 228,188 shares remaining. This transaction was an automatic "sell to cover" to fulfill tax liabilities arising...

Zhou Rong, Senior EVP of Production Center at Amphastar Pharmaceuticals, Inc., reported a sale of 3,187 shares of Common Stock on September 2, 2026. The shares were sold at a weighted average price of $23.6291, with prices ranging from $23.62 to $23.69. Following this transaction, Mr. Rong directly owns 169,203 shares....

Jenisch Jan Philipp, Chairman & CEO of Amrize Ltd, reported a series of ordinary share transactions on September 2, 2026. These transactions included the acquisition of 10,000 shares at $42.37, 15,000 shares at $42.53, and 1,000 shares at $42.44. Additionally, 2,000 shares were acquired at $42.53 and another 2,000 shar...

This Form 4 filing details transactions made by Sarah Zibbel, EVP & Chief HR Officer of The Andersons, Inc. On September 1, 2026, Zibbel acquired 69.675 shares of Common Stock in lieu of cash dividend (transaction code A). On September 2, 2026, Zibbel disposed of 602 shares of Common Stock for a price of $64.87 per sha...

Steven I. Sarowitz, a director at Angel Studios, Inc., reported the purchase of 10,979 shares of Class A Common Stock on September 1, 2026. The acquisition was made at a weighted average price of $4.2741 per share, with individual transactions ranging from $4.1750 to $4.3000. Following this transaction, Sarowitz now di...

This Form 4 filing reports insider purchases by Lester B. Knight, a director of Aon plc (NYSE: AON), on September 2, 2026. Knight acquired a total of 20,000 Class A Ordinary Shares through a Family Partnership (indirect ownership), executed in six separate transactions at weighted average prices ranging from $325.63 to...

This Form 4, filed September 3, 2026, reports the disposition of all equity holdings by directors and affiliated filers of Apogee Therapeutics, Inc. (APGE) following the completion of the merger with an AbbVie Inc. subsidiary. Reporting owners Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Tomas Kis...

This filing details transactions by Nimish P. Shah, a director at Apogee Therapeutics, Inc. (APGE), on September 3, 2026. The transactions, executed in connection with the acquisition of Apogee by AbbVie Inc., involved the disposition of 1,750,000 shares of Common Stock at $135.11 per share. Additionally, Mr. Shah disp...

Michael Thomas Henderson, the Chief Executive Officer of Apogee Therapeutics, Inc., reported a disposition of 920,941 shares of Common Stock on September 3, 2026, valued at $0.00 per share, as detailed in footnote F1. This transaction was part of the merger agreement between Andor LLC, Andor Merger Co., Apogee Therapeu...

On September 3, 2026, Lisa Bollinger, a director of Apogee Therapeutics, Inc. (APGE), reported the disposition of all her outstanding stock options in connection with the merger of the company with an affiliate of AbbVie Inc. under the Agreement and Plan of Merger dated June 18, 2026. The Form 4 reflects the cancellati...

This filing details transactions by Jane Henderson, Chief Financial Officer of Apogee Therapeutics, Inc. On September 3, 2026, Henderson disposed of 158,371 shares of common stock as part of a merger agreement with Andor LLC, Andor Merger Co., and AbbVie Inc. Additionally, vested stock options totaling 175,345, 124,962...

On September 3, 2026, Jennifer A. Fox, a director at Apogee Therapeutics, Inc. (APGE), reported the disposition of 34,824 shares of Common Stock. This disposition was part of the merger agreement with Andor LLC, Andor Merger Co., and AbbVie Inc. Additionally, Fox disposed of vested stock options, including 10,370 optio...

This Form 4 reports transactions by Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, Inc. (APGE), in connection with the Agreement and Plan of Merger dated June 18, 2026, among Andor LLC, Andor Merger Co., Apogee, and AbbVie Inc. On September 2, 2026, the reporting owner disposed of 1,375 shares of common...

This filing details the disposition of securities by Jones William A JR, a director at Apogee Therapeutics, Inc. On September 3, 2026, 34,824 shares of Common Stock were disposed of. Additionally, stock options to purchase 10,370, 14,461, and 7,657 shares of Common Stock were also disposed of. These transactions occurr...

This filing details a Form 4 filing for Apogee Therapeutics, Inc. (APGE), reporting transactions by Mark C. McKenna, a director. On September 3, 2026, McKenna disposed of 20,000 shares of Common Stock and several stock options. These transactions were executed under the terms of a Merger Agreement with Andor LLC, Andor...

Albert L. Lord, a director of AppTech Payments Corp. (NASDAQ: APCX), filed a Form 4 with the SEC reporting open-market purchases of the company's common stock on three consecutive trading days. On September 1, 2, and 3, 2026, Lord purchased 20,000 shares each day at weighted average prices of $0.3538, $0.3583, and $0.3...

Jennifer Newstead, SVP, GC and Government Affairs at Apple Inc. (AAPL), reported a sale of 1439 shares of Common Stock on September 1, 2026. The transaction was executed at a price of $317.01 per share, resulting in a total sale value of $456,103.79. Following this transaction, Newstead directly owns 35,790 shares of A...

This filing details two transactions by Noam Arkind, Chief Technology Officer and Director of Arbe Robotics Ltd. On September 2, 2026, Arkind sold 31,700 ordinary shares at $0.6403 per share, leaving 1,592,282 shares. On September 3, 2026, Arkind sold an additional 31,000 ordinary shares at $0.6357 per share, resulting...

Chantelle Yvette Breithaupt, Senior Vice President and CFO of Arista Networks, Inc. (ANET), reported the sale of 612 shares of Common Stock on September 1, 2026. The transaction, executed at a price of $195.77 per share, was part of a Rule 10b5-1 trading plan initiated on December 11, 2025, and modified on June 2, 2026...

This filing details two transactions by Noam Arkind, Chief Technology Officer and Director of Arbe Robotics Ltd. On September 2, 2026, Arkind sold 31,700 ordinary shares at $0.6403 per share, leaving 1,592,282 shares. On September 3, 2026, Arkind sold an additional 31,000 ordinary shares at $0.6357 per share, resulting...

Peter Oluoch Owino, Chief Accounting Officer of Arq, Inc., acquired 100,000 shares of Common Stock and 61,047 Performance Share Units (PSUs) on September 1, 2026. The Common Stock acquisition was an employment inducement award, with vesting dates in 2027, 2028, and 2029. The PSUs were granted under the company's 2026 O...

K. Charles Janac, President and CEO, reported a sale of 100,000 shares of Common Stock in Arteris, Inc. (AIP) on September 1, 2026. The sale was executed as part of a 10b5-1 trading plan adopted on December 12, 2025. The shares were sold at a weighted average price of $20.7497, with individual sale prices ranging from ...

This filing details a stock sale by Bayview Legacy, LLC, a significant shareholder in Arteris, Inc. (AIP). On September 1, 2026, Bayview Legacy, LLC, managed by K. Charles Janac, sold 100,000 shares of common stock. The sale was conducted under a Rule 10b5-1 trading plan. The reported sale price of $20.7497 is a weight...

On September 2, 2026, Lars Holtug, a director of Ascendis Pharma A/S (NASDAQ: ASND), disposed of 236 ordinary shares in a market sale at a price of $264.1296 per share, for an approximate total transaction value of $62,334. The transaction was reported on a Form 4 filed on September 3, 2026, and was coded as a sale ("S...